Altace Co-Promotion Lawsuit Spurs Question About King's Ability To Launch Nebivolol
This article was originally published in The Pink Sheet Daily
Executive Summary
An investment firm says Wyeth's lawsuit alleging King failed to meet its detailing obligations for Altace raises "concern" that King will lack the manpower needed to promote Mylan's beta blocker. Mylan says the King acquisition is the best strategy for maximizing nebivolol.